P Flory

Mucosal healing in inflammatory bowel diseases: a systematic review

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004

OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines

Rheumatoid arthritis

Rheumatoid arthritis

European evidence based consensus for endoscopy in inflammatory bowel disease

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C

Differentiating the efficacy of the tumor necrosis factor inhibitors

Intra-articular treatments in osteoarthritis: from the symptomatic to the structure modifying

Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis

Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005

Crohn's disease

Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria

Efficacy and safety of intraarticular hyaluronic acid in the treatment of hip osteoarthritis: a systematic review

Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges

Crohn's disease

Pyoderma gangrenosum: an updated review

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

Efficacy of non-invasive elastometry on staging of hepatic fibrosis

Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial

Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped

What is the evidence for viscosupplementation in the treatment of patients with hip osteoarthritis? Systematic review of the literature

Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies

Rheumatoid Arthritis

Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management

Glycosaminoglycans and their proteoglycans: host‐associated molecular patterns for initiation and modulation of inflammation

The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis.

Tropical pyomyositis (myositis tropicans): current perspective

Comparison of the efficacy of lower and higher molecular weight viscosupplementation in the treatment of hip osteoarthritis

Hip osteoarthritis: short-term efficacy and safety of viscosupplementation by hylan G-F 20. An open-label study in 22 patients

Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritis

[Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha].

Pyomyositis: cervical localization.

Treatment of pyoderma gangrenosum with colchicine